Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Dig Liver Dis ; 49(2): 188-196, 2017 Feb.
Article in English | MEDLINE | ID: mdl-27939923

ABSTRACT

Non-alcoholic fatty liver disease (NAFLD) is characterized by excessive lipid hepatic accumulation. Here, we investigated whether a reduction of CD98 expression mediated by CD98 siRNA-loaded nanoparticles (NPs) could attenuate liver disease markers in a mouse model of NAFLD. NPs were generated using a double emulsion/solvent evaporation technique. Mice fed a high fat diet for 8 weeks to induce fatty liver were treated with vein tail injections of CD98 siRNA-loaded NPs. In vitro, HepG2 treated with CD98 siRNA-loaded NPs showed significant downregulation of CD98 leading to a significant decrease of major pro-inflammatory cytokines and markers. In vivo, CD98 siRNA-loaded NPs strongly decreased all markers of NAFLD, including the blood levels of ALT and lipids accumulation, fibrosis evidence and pro-inflammatory cytokines. In conclusion, our results indicate that CD98 appears to function as a key actor/inducer in NAFLD, and that our NPs approach may offer a new targeted therapeutic for this disease.


Subject(s)
Fusion Regulatory Protein-1/genetics , Gene Silencing , Non-alcoholic Fatty Liver Disease/therapy , RNA, Small Interfering/genetics , Animals , Biomarkers/blood , Diet, High-Fat , Disease Models, Animal , Down-Regulation , Female , Humans , Mice , Nanoparticles/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...